BACKGROUND: the management of recurrent rectal cancer is challenging. at the present time, pelvic exenteration with en bloc sacrectomy offers the only hope of a lasting cure.
t he management of recurrent rectal cancer (RRC) is challenging. [1] [2] [3] [4] [5] nonsurgical management of RRC either with radiotherapy alone or together with chemotherapy may improve symptoms, but 5-year survival rates, which are approximately 5%, are extremely poor. 6 Radical resection of the tumor along with removal of any involved organs offers the only hope for tumor-free survival. 6 Recurrent rectal cancer may directly invade any of the anterior, posterior, central, or lateral pelvic compartments and nearby organ or organs including the presacral fascia or the sacrum itself. 4, 7 Patients undergoing intended curative surgery for RRC with sacral bone involvement need to undergo en bloc sacrectomy as part of pelvic exenteration. Resection of these tumors requires specialized pelvic oncology expertise in multivisceral resection with input from several specialties, including plastic surgery, urology, vascular surgery, and orthopedic teams.
2,7,10 a multidisciplinary approach resulting in en bloc pelvic exenteration of all involved structures gives the greatest hope of complete resection with negative margins (>1-mm resection margin: R0), which has been reported by some authors to be the most significant prognostic indicator for patients with RRC. 2, 6, [11] [12] [13] [14] nevertheless, considerable morbidity has been reported with exenterative procedures. 1 Pelvic exenteration with sacrectomy is thought to be associated with the greatest rates of major postoperative morbidity for patients with RRC; rates of morbidity have been reported by some studies to correlate with the height of the sacral transection.
3,15 the most commonly described method for performing these surgical procedures is an anterior -supine followed by posterior -prone approach.
2,16 long operative times and prone positioning have been proposed as increasing the risk of cardiorespiratory complications. 7, 17 in addition, iliac vessel excision and sacral transection may also be associated with lifethreatening blood loss. Radiotherapy often makes pelvic dissection more challenging, and, although neoadjuvant chemoradiotherapy has been demonstrated to improve local recurrence rates for advanced primary rectal cancers, the effectiveness of reirradiating patients with RRC has yet to be definitely established. 5 exenterative surgery with en bloc sacrectomy may also be associated with very high rates of minor morbidity. 7 Wound healing problems are reported to occur commonly in patients undergoing these procedures despite myocutaneous flap reconstruction, especially in the setting of prior radiotherapy. 1 significant rates of postoperative morbidity are also described by some authors following urological reconstruction. Reoperative procedures to manage ureteric anastomotic problems after reimplantation are also not uncommon. 18, 19 Despite these very significant risks, at the present time, pelvic exenteration with en bloc sacrectomy offers the only hope of a lasting cure for patients with RRC directly invading or adherent to the sacrum. 1, 5, 20 Without an attempt at surgical excision, the majority of these patients face a mean overall survival of approximately 7 months. 21 in the light of this finding, the purpose of this study was to conduct a systematic review of the published literature to more accurately determine morbidity, mortality, and survival rates for patients undergoing sacrectomy as part of an exenterative procedure for RRC.
METHODS
to identify relevant articles for this review, 2 of the authors (s.a. and J.m.) conducted a systematic search of the Pubmed database. the inclusion criterion defined for this review was that identified studies reported survival data for recurrent rectal adenocarcinoma (RRC). non-english language publications, case reports, and articles reporting outcome measures for pathologies other than rectal adenocarcinoma were excluded. a record of included and excluded articles is presented in the PRisma flow diagram ( fig. 1 ). 22 the authors used multiple techniques and terminologies to identify as many relevant published articles as possible. the final search was conducted on may 3, 2016 with no time restriction on included studies. the following search terms were used both in isolation and combination: "rectal cancer sacrum"; "rectal cancer sacrectomy"; "rectum sacrectomy"; and "sacrectomy." the authors screened the abstract and text of all publications. articles that met the inclusion criterion were selected and included within this study following agreement among all the authors. the references of reviewed articles were also examined to identify further relevant articles. the data from the included studies were extracted and recorded on a microsoft excel spread sheet. the abstracted data included number of patients in the study, patient demographics, surgical interventions, neoadjuvant therapies, resection margin status, mortality, morbidity, and survival data. any postoperative complication during the postoperative stay greater or equal to a Clavien-Dindo classification score of iii was considered as a major complication.
2,23 outcome measures were compared between high (s1-s2) and low (s3 and below) sacral transection.
RESULTS
Literature Search a search conducted on may 3, 2016, of the Pubmed database identified 607 articles. the PRisma flow chart shows the summary of the search results ( fig. 1 ). of the 20 articles that were potentially eligible for systematic review, 8 were excluded because of lack of survival data, 4 were excluded because of the inclusion of patients with pathologies other than recurrent rectal adenocarcinoma, whereas 1 study was excluded because the patients included in the article had subcortical resection of sacrum.
Study Population the 7 articles published between December 2004 and november 2014 assessed by this review reported a total of 220 patients with recurrent rectal adenocarcinoma (RRC) and are summarized in table 1. of the 220 patients, 122 (55%) received neoadjuvant chemoradiotherapy at some point before surgery for RRC. a total of 62 (28%) patients underwent rectal excision with en bloc high sacrectomy, and 155 (70%) patients underwent rectal excision with low sacrectomy. in addition, 19 (9%) patients underwent other bony resections in addition to rectal resection and sacrectomy, whereas 99 patients required ileal conduit construction.
for all patients, the median operative time was 717 (range, 570-992) minutes, with the median blood loss reported as 3700 (range, 1725-6200) ml. in 172 (78%) cases, an R0 resection was achieved, with 45 R1 and 3 R2 resections occurring in the remainder of the patient cohort. median length of stay for all patients was 22 (range, 15-46) days. Within the first 30 days of the postoperative period, 4 deaths (2%) occurred in the assessed cohort, and major morbidity occurred in 114 (52%) of the 220 patients.
the median follow-up for this group was 33 (range, 17-60) months. of the 172 patients who underwent R0 resection, 123 patients were alive (72%), of which 95 (55%) were disease free at the last recorded follow-up. in contrast, 8 (18%) of the 45 patients who underwent R1 resection were alive, of which no patient was disease free at the last recorded follow-up assessment.
Surgical Outcome Measures by Height of Sacrectomy
five of the seven studies, 3 reporting a total of 105 patients, presented data in a manner that allowed duration of surgical procedure, intraoperative blood loss, completeness of resection, length of postoperative hospital stay, and postoperative complications to be assessed by the height of sacral transection. the results of this subanalysis are summarized in table 2. high sacrectomy was performed in 54 cases and low sacrectomy was performed in 49 cases within this patient cohort.
the median operative time for high sacrectomy was 13.3 hours (range, 10.4-21.2), which was higher than the reported operative times for low sacral transection (11.5 hours (range, 11.5-14.8)). median intraoperative blood loss for patients undergoing high sacral transection was 4487 (3200-7500) ml. as might be expected, low sacrectomy was associated with a lower median intraoperative blood loss of 2630 (1725-5750) ml.
the rate of complications appears to increase with more proximal sacral transection. a total of 33 (61%) of the 54 patients who underwent high sacrectomy developed at least 1 major complication. in, contrast, only 23 (45%) of the 49 patients undergoing low sacrectomy had one or more significant reported complication. median length of postoperative hospital stay for patients undergoing high sacrectomy in this subgroup analysis was 40 (range, 19.5-53) days. With a lower sacral transection level median length of stay was lower. the cohort undergoing low sacrectomy had a median stay of 24.5 (range, 15-43.5) days.
Resection Margin Status by Height of Sacrectomy
four of the seven studies, 1, 15, 24, 25 reporting a total of 82 patients, provided data that allowed height of sacrectomy and resection margin status to be compared (table 3) . Within this cohort, 33 high and 49 low sacrectomies were performed. four patients (11%) within the high sacrectomy group underwent R1 resection in comparison with 11 (23%) patients in the low sacrectomy group.
DISCUSSION
this review identified 220 patients reported in the published literature with RRC invading the sacrum and Case study (n = 9) FIGURE 1. This PRISMA flow diagram summarizes the literature search results and selection processes applied for our systematic review. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
demonstrates that R0 resection can be achieved in 78% of this cohort, despite that one-quarter of those studied underwent rectal excision with en bloc high sacrectomy because of extensive disease. 1, 2, 11, 15, 24, 26, 27 Complete pathological excision with greater than 1-mm clearance (R0) at all margins was associated with a 55% disease-free survival (Dfs) and a 72% overall survival at a median of 33 months follow-up in the cohort as a whole. [1] [2] [3] 11, 15, 17, 24, 25, 28, 29 this systematic review demonstrates that complete resection of the tumor is the most predictive factor of survival. therefore, it is paramount to achieve R0 resection to balance the risks posed by surgical interventions of this magnitude. 15 Proximity or involvement of vital structures in the pelvis, postradiotherapy changes, and narrow pelvic anatomy are some of the factors that make these procedures even more challenging. therefore, it is important to refer these patients to centers dedicated to this surgery that are equipped with specialty teams and facilities. 10 When outcome measures were stratified by height of sacral transection, postoperative complications and median length of stay were found to decrease with more distal transection levels. of note, however, was the observation that low sacrectomy was associated with a higher incidence of R1 resection than high sacrectomy. some studies found viable tumor at the resection margins associated with the resected sacral edge. 15 thorough assessment of preoperative imaging before embarking on these procedures and placement of a marker such as a K-wire under fluoroscopic guidance at the correct sacral height may overcome this problem.
until recently, abdominosacral resection has been considered as the only curative surgical option for patients with RRC involving the sacrum. 15 although, with this method, R0 resection of RRC involving high sacral bone is achievable, concerns remain regarding postoperative complication rates and pelvic instability following high sacral resections. 30 Recently published techniques such as anterior cortical resection and posterior segmental excision demonstrated that an R0 resection can be achieved for highly selected patients. 30, 31 shaikh etal 31 published a novel technique of subcortical resection performed on 5 patients who had s1-s2 sacral bony involvement. the technique resulted in R0 resection specimens for all 5 patients. similarly, Brown et al 30 described another technique of segmental resection to treat involvement of the proximal sacrum, while preserving uninvolved distal and contralateral sacral bone. Both these techniques offer the opportunity to achieve R0 resection, while minimizing postoperative complications in comparison with high sacral transection. Values stated are n (%) or median (range).
b In a total of 220 patients, there were 160 men (73%) and 60 women (27%). the use of intraoperative radiotherapy in RRC surgery is supported by some of the published literature. a systematic review of 1211 RRC patients treated with this therapy was conducted by mirnezami et al 32 and demonstrated significant improvements in local control, overall Dfs, and overall survival. another study by hyngstrom et al 33 concluded that patients with R0 resection and R1 resection benefited from intraoperative radiotherapy delivered via brachytherapy with Dfs of 72% for R0 patients and 60% for R1 patients.
Considerable morbidity was encountered in the patient cohort reported by our review, with a 52% reported rate of major postoperative complications; however, postoperative mortality was relatively low at 2%. three of the four patients died of pelvic sepsis, and 1 patient died of cardiac arrest on the third postoperative day. the most common major morbidity was pelvic abscess that required intervention. Perineal wound complications following RRC surgery have been reported to vary from 25% to 60% in the published literature. 34 as a consequence, myocutaneous flap reconstruction and protracted pelvic/perineal drainage may be necessary for these patients. We could not analyze the effectiveness of soft tissue reconstruction from the data assessed in this study; however, there are multiple reports in other disease settings that demonstrate that this approach reduces infection rates and wound dehiscence and improves wound healing. 34, 35 to our knowledge, there are no published systematic reviews of rectal resection with en bloc sacrectomy for RRC available with which to compare our analyses. therefore, this study provides a unique overview of the currently available data and summarizes clinical outcome measures following surgical intervention of this magnitude. although the data contained in this review are inevitably skewed by virtue of the best-performing centers reporting their experience, these outcome measures set a benchmark of what can be achieved for patients with RRC at the present time. the incremental benefits of new approaches such as the use of mRi to plan surgical intervention, or neoadjuvant therapy as a means of downstaging RRC invading the sacrum before surgery, could not be assessed by this study. nevertheless, it is expected that these advances in perioperative assessment and multimodal therapy may improve clinical outcome measures still further in the future.
Review of the data included in this study has once again demonstrated the importance of complete pathological excision as an important predictor of Dfs. the question that remains uncertain following this review is the role of rectal excision with en bloc sacrectomy for palliation of the local symptoms of RRC. even when these patients are managed with palliative chemotherapy and aggressive symptom control, their quality of life rapidly declines because of a number of problems, including the pain caused by bone or neural involvement, or perineal ulceration. 5 this has led some centers to undertake palliative procedures with a planned R2 resection, in the hope that such interventions might improve quality of life. the significant postoperative complication rates and poor medium-term survival data in the R1 cohort (no Dfs at a median of 33 months) demonstrated by this study call into question the risk/benefit of this approach. although the benefit of this strategy is yet to be demonstrated in the published literature, in highly selected cases, when the patient is extensively counseled and the necessary surgical skill set is available, these procedures may still be deemed appropriate for individual cases.
as with all studies, this work has both strengths and weaknesses. this is the first review to assess clinical outcome measures of patients undergoing rectal excision with en bloc sacrectomy and thus it adds significantly to the published literature. this review has also focused on the key clinical outcome measures and medium-term survival data, which will inform discussions with patients who are candidates for these procedures, in addition to offering a benchmark against which centers undertaking these interventions can audit their results.
Despite these benefits, the studies assessed by this review were retrospective. furthermore, some potentially eligible patients were excluded from studies reporting mixed pathologies or limited outcome measures because of a lack of raw data. attempts were made to obtain raw data from the corresponding authors of these studies, but these attempts were unsuccessful. it is important to note that almost half of the patients reported in this article are from 2 centers, which is another limitation of this review. 26, 36 finally, improvement in radiological staging, advances in surgical technique, chemotherapy agents, delivery method, and perioperative care have led to improved survival in patients undergoing RRC surgery. 9, 37 Given that we have included early studies as well as recent studies, the outcome measures reported by this review are inevitably subject to bias.
there is a clear need for large studies of patients undergoing sacrectomy for RRC surgery with prospectively recorded data, which is likely to require international collaboration between specialist centers undertaking this work. until studies of that magnitude are undertaken, the data presented in this review will be of significant use to both those patients undergoing surgery for RRC, oncologists treating patients who have rectal cancer, and the surgeons who undertake these procedures.
CONCLUSIONS
sacrectomy performed for patients with RRC is associated with significant postoperative morbidity. nevertheless, 43% of patients eligible for this surgery may benefit from Dfs for nearly 3 years. R0 resection remains the strongest predictor of Dfs in the medium term. the data presented by this review will aid discussions with patients who are candidates for these operations, in addition to offering a benchmark against which centers undertaking these interventions can audit their results in the future.
